Prokidney Corp. (PROK): Total Assets
$335.57M
As of 2025-12-31
$249.02M
As of 2026-06-30
-13.5%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $335.57M | -23.9% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $441.07M | +4.9% | 2026-03-18, Balance as of period end |
| 2023-12-31 | $420.55M | -18.8% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $518.00M | n/m | 2024-03-22, Balance as of period end |
| 2021-12-31 | $40.30M | n/a | 2023-03-28, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Prokidney Corp. (PROK) | 2025-12-31 | $335.57M | -23.9% |
| ImageneBio, Inc. (IMA) | 2025-12-31 | $152.98M | +860.8% |
| Pluri Inc. (PLUR) | 2026-06-30 | $24.88M | -35.7% |
| Inhibrx Biosciences, Inc. (INBX) | 2025-12-31 | $146.48M | -19.0% |
| Scinai Immunotherapeutics Ltd. (SCNI) | 2025-12-31 | $11.63M | -13.5% |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | $61.88M | -36.3% |
| Outlook Therapeutics, Inc. (OTLK) | 2025-09-30 | $18.58M | -35.5% |
| Humacyte, Inc. (HUMA) | 2025-12-31 | $116.37M | -15.6% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $88.53M | +26.3% |
Compare PROK, IMA, PLUR, INBX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗